New Study Reports Favorable Results for Intuitive Surgical’s Flexible Robotics Platform
November 02 2017 - 9:00AM
Results from the first clinical study evaluating a new flexible
robotics platform under development by Intuitive Surgical were
presented at the CHEST Annual Meeting on Wednesday. The findings
suggest that using the platform is a safe and feasible approach to
sample lung tissue.
Intuitive Surgical’s robotic-assisted, catheter-based technology
is being designed to access hard-to-reach areas of the body through
natural openings, like the mouth. When applied in the lungs,
its aim is to enable early lung cancer diagnoses by accessing and
sampling tissue from small nodules in difficult-to-reach areas.
This single-center study at Australia’s Royal Brisbane and
Women’s Hospital was led by principle investigator, David Fielding,
MD, a thoracic physician and Director of Bronchology, and
co-investigator Farzad Bashirzadeh, MD, a respiratory and sleep
physician at the hospital. The 30-patient study evaluated both the
safety and feasibility of the platform.
In the study, a majority of the target nodules were smaller than
two centimeters in diameter. In 29 of 30 cases, the
pre-planned target area was reached and a sample suitable for
assessment was obtained. Additionally, no device-related adverse
events, or instances of pneumothorax or excessive bleeding
occurred, suggesting a strong safety profile.
“I was able to reach nodules in the peripheral lung that I
wouldn’t have been able to reach before,” said Dr. Fielding.
“The robotic-assisted technology in sampling facilitates diagnosis
at a stage in which most patients wouldn’t yet know that they have
cancer. Early diagnosis should allow us to start care plans
for patients earlier and offer curative treatments.”
The flexible robotics platform from Intuitive Surgical is still
under development, not yet 510(k) cleared by the U.S. Food and Drug
Administration and not for sale. The safety and effectiveness
of this platform have not been established. The study was
funded by Intuitive Surgical.
About Intuitive Surgical, Inc.Intuitive
Surgical, Inc. (Nasdaq:ISRG), headquartered in Sunnyvale,
Calif., is a global technology leader in robotic-assisted,
minimally invasive surgery. Intuitive Surgical develops,
manufactures and markets robotic-assisted technologies. The
Company strives to make surgery more effective, less invasive and
easier on surgeons, patients and their families.
Forward-Looking StatementsThis press release
contains forward-looking statements, including statements regarding
the flexible robotics platform as a safe and feasible approach to
sample lung tissue, the ability of platform application in the
lungs to enable early lung cancer diagnoses, the strong safety
profile of the platform, and enabling physicians to start care
plans for patients earlier and offer curative treatments.
These forward-looking statements are necessarily estimates
reflecting the best judgment of our management and involve a number
of risks and uncertainties that could cause actual results to
differ materially from those suggested by the forward-looking
statements. These forward-looking statements should, therefore, be
considered in light of various important factors, including, but
not limited to, the following: the impact of global and regional
economic and credit market conditions on healthcare spending;
healthcare reform legislation in the United States and its impact
on hospital spending, reimbursement and fees levied on certain
medical device revenues; changes in hospital admissions and actions
by payers to limit or manage surgical procedures; the timing and
success of product development and market acceptance of developed
products; the results of any collaborations, in-licensing
arrangements, joint ventures, strategic alliances or partnerships;
procedure counts; regulatory approvals, clearances and restrictions
or any dispute that may occur with any regulatory body; guidelines
and recommendations in the healthcare and patient communities;
intellectual property positions and litigation; competition in the
medical device industry and in the specific markets of surgery in
which we operate; unanticipated manufacturing disruptions or the
inability to meet demand for products; the results of legal
proceedings to which we are or may become a party; product
liability and other litigation claims; adverse publicity regarding
the Company and the safety of our products and adequacy of
training; our ability to expand into foreign markets; and other
risk factors under the heading “Risk Factors” in our report on Form
10-K for the year ended December 31, 2016, as updated by our other
filings with the Securities and Exchange Commission. Statements
using words such as “estimates,” “projects,” “believes,”
“anticipates,” “plans,” “expects,” “intends,” “may,” “will,”
“could,” “should,” “would,” “targeted” and similar words and
expressions are intended to identify forward-looking statements.
You are cautioned not to place undue reliance on these forward
looking statements, which speak only as of the date of this press
release. We undertake no obligation to publicly update or release
any revisions to these forward-looking statements, except as
required by law.
PN 1042795-US Rev A 10/2017
ContactGlobal Public
AffairsIntuitive SurgicalEmail: corp.comm@intusurg.comU.S.
Tel: +1 408.523.7337
Intuitive Surgical (NASDAQ:ISRG)
Historical Stock Chart
From Mar 2024 to Apr 2024
Intuitive Surgical (NASDAQ:ISRG)
Historical Stock Chart
From Apr 2023 to Apr 2024